Epsilogen Ltd

Epsilogen Ltd company information, Employees & Contact Information

Explore related pages

Related company profiles:

Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.

Company Details

Employees
30
Founded
-
Address
Waterfront, Arc West London,manbre Road,united Kingdom
Phone
+44 (0) 203 657 7612
Email
in****@****ics.com
Industry
Biotechnology
HQ
Hammersmith
Looking for a particular Epsilogen Ltd employee's phone or email?

Epsilogen Ltd Questions

News

Epsilogen Appoints Cristina Oliva, MD, PhD as Chief Medical Officer - citybiz

Epsilogen Appoints Cristina Oliva, MD, PhD as Chief Medical Officer citybiz

Epsilogen names Cristina Oliva as CMO - The Pharma Letter

Epsilogen names Cristina Oliva as CMO The Pharma Letter

Epsilogen appoints Cristina Oliva as chief medical officer - PMLiVE

Epsilogen appoints Cristina Oliva as chief medical officer PMLiVE

Epsilogen acquires TigaTx to expand pan-isotope cancer antibody pipeline - Pharmaceutical Technology

Epsilogen acquires TigaTx to expand pan-isotope cancer antibody pipeline Pharmaceutical Technology

Epsilogen acquires TigaTx to drive pan-isotype cancer antibody innovation - FirstWord Pharma

Epsilogen acquires TigaTx to drive pan-isotype cancer antibody innovation FirstWord Pharma

Epsilogen Acquires TigaTx - citybiz

Epsilogen Acquires TigaTx citybiz

New isotype player enters after IGM's exit | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

New isotype player enters after IGM's exit | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Epsilogen obtains MHRA approval for Phase Ib trial of ovarian cancer treatment - Clinical Trials Arena

Epsilogen obtains MHRA approval for Phase Ib trial of ovarian cancer treatment Clinical Trials Arena

Epsilogen completes first clinical trial of IgE antibody to treat cancer - Labiotech.eu

Epsilogen completes first clinical trial of IgE antibody to treat cancer Labiotech.eu

Epsilogen Ltd completes £12.5m Series B expansion - European Biotechnology Magazine

Epsilogen Ltd completes £12.5m Series B expansion European Biotechnology Magazine

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial - Nature

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial Nature

Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into new class of cancer drug - Fierce Biotech

Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into new class of cancer drug Fierce Biotech

Epsilogen raises Series B funds to develop cancer therapy - Pharmaceutical Technology

Epsilogen raises Series B funds to develop cancer therapy Pharmaceutical Technology

First ever large-scale GMP manufacturing of therapeutic IgE antibody achieved in the UK - BioSpectrum Asia

First ever large-scale GMP manufacturing of therapeutic IgE antibody achieved in the UK BioSpectrum Asia

King's immuno-oncology spin-out gains £30m funding - King's College London

King's immuno-oncology spin-out gains £30m funding King's College London

ARC West London Motherlabs reaches full occupation - UK Property Forums

ARC West London Motherlabs reaches full occupation UK Property Forums

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant